Removal of Torus Palatinus Template

Removal of torus palatinus.

RMH: Medical history reviewed/updates
Vitals: BP/pulse; other vitals if indicated

Torus description: Torus description
Size: Size
Shape: Shape
Indication: Indication/diagnosis
Radiographs/images: Radiographs/images reviewed/taken and findings
Prosthesis fabrication.
Trauma from mastication.
Patient request.

Consent: Consent/PARQ reviewed; signed/verbally obtained

Anesthesia: Anesthetic used
Carps: Carpules/amount

Surgical procedure support: Specific site/teeth, indication, and medical necessity
Operative details: Surgical access, tissue/bone removed or repositioned, closure materials
Image/specimen support: Radiographs/photos/specimen/lab as applicable

Procedure:
Midline incision made on palate.
Mucoperiosteal flap elevated.
Torus exposed.
Torus sectioned with bur.
Segments removed.
Area smoothed and contoured.
Copious irrigation.
Flap repositioned.
Sutured with: Suture material/size
Hemostasis achieved.

Complications: None or describe.

Patient tolerance: Tolerance/response.

Post-op instructions: Instructions reviewed.
Soft diet.
Rx: Prescription or none

NV: Next visit

Documentation requirements

D7472 documentation does three things: prove the bony mass is a true midline palatal torus (not a lateral exostosis or hyperplastic tissue), prove a covered indication (most commonly pre-prosthetic preparation for a maxillary denture), and prove the surgical procedure was actually performed — Y-incision flap, bony reduction, recontouring, primary closure. The chart note carries the burden because most carriers route D7472 to manual review when it is billed without a same-arch removable prosthesis on the treatment plan or recent claim history. A defensible note includes:

• Site and laterality — explicit "midline hard palate" language. "Torus palatinus, midline maxillary palate" beats "palatal bony prominence." Note the anteroposterior position relative to the rugae and the posterior palatal seal area when the torus extends posteriorly.
• Torus dimensions — measured in millimeters: anterior-posterior length, mediolateral width, and dome height (vertical projection from the surrounding palatal mucosa). "Lobulated torus palatinus, ~22 mm A-P x 14 mm M-L x 6 mm vertical projection" is concrete; "large torus" is not. Dimensions drive whether the torus is sectioned (for a flat or dome-shaped torus >~5 mm) or removed in pieces (for a lobulated or pedunculated torus). Carriers often request this measurement when a claim is reviewed.
• Torus shape / morphology — flat, dome (spindle), nodular / lobulated, pedunculated. The morphology drives the surgical approach (osteotome cleavage along the midline septum for flat tori vs. bur sectioning into segments for lobulated tori) and predicts the risk of mucosal perforation.
• Indication / diagnosis — explicit, covered indication. The four reportable buckets are: (a) prosthetic interference with a planned or existing maxillary denture or partial — strongest carrier-acceptable indication; (b) traumatic — recurrent ulceration of overlying mucosa from mastication, sharp lobulated topography; (c) functional — speech, swallowing, or airway compromise; (d) pathology-related — interference with another surgical procedure (obturator placement, orthognathic surgery, implant osteotomy that requires palatal vault clearance). "Pre-prosthetic — torus prevents seating of planned maxillary complete denture (D5110), causes rocking and acrylic fracture risk" is the prototypical reimbursable indication.
• Prosthetic plan documentation — when the indication is pre-prosthetic, name the planned removable prosthesis code(s) (D5110, D5120 if mandibular partner planned, D5130 immediate denture, D5213 cast partial maxillary, D5214 cast partial mandibular for the partner arch, D5863 / D5864 overdentures). The same-claim or near-future presence of a removable prosthodontic code is the single strongest piece of medical-necessity evidence on review. For pre-existing dentures, document the date of fabrication, the specific area of acrylic relief or fracture, and any history of mucosal ulceration.
• Pre-op imaging — pre-op intraoral photo of the torus is the single most-requested piece of documentation when D7472 is reviewed. A periapical or panoramic radiograph showing the bony prominence is helpful but not always diagnostic of palatal tori (the projection often obscures midline anatomy). CBCT (D0364-D0368) is increasingly used when the torus is large and the surgeon needs to assess vault contour, palatal artery position, nasal floor proximity, or thickness of the overlying mucosa; bill the imaging code separately and document the indication. A pre-op clinical photo labeled with patient identifier, date, and "midline torus palatinus, pre-op" is the strongest single piece of audit evidence.
• Medical and dental history — reviewed today; flag bisphosphonates / anti-resorptives (MRONJ risk for any oral surgical bone-removal procedure; nitrogen-containing IV bisphosphonates and denosumab the highest), anticoagulants (with INR or recent dose timing for warfarin / DOACs, given the rich palatal vascular supply), antiplatelet therapy, head/neck radiation history (osteoradionecrosis risk), uncontrolled diabetes, immunosuppression, and IE prophylaxis indication when applicable. The greater palatine artery's proximity to a large torus makes hemostasis a more meaningful issue here than for most pre-prosthetic procedures.
• Vitals — pre-op BP and pulse; many state boards and most surgical practices require these on operative visits.
• Informed consent / PARQ — risks specific to torus palatinus removal: palatal mucosal perforation (the overlying mucosa is often thin, <1 mm, and tears during reflection or undermining), postoperative hemorrhage (the greater palatine artery courses through the soft tissue lateral to the torus; injury during flap reflection is the dominant intraoperative bleeding risk), nasal floor or sinus exposure (rare but reportable when the torus is large and the surgeon over-reduces), flap necrosis / dehiscence (the palatal flap relies on a thin, midline-segmented blood supply and can slough if the donor mucosa is excessively thinned), prolonged healing under a palatal stent, post-op pain disproportionate to other oral surgical procedures (the palatal periosteum is densely innervated), infection, scar contracture with theoretical airway or speech impact for very large defects, need for additional surgery if recurrence (rare) or incomplete removal occurs, and alternatives (no treatment with prosthesis modification or relief, smaller staged reduction, referral to OMS for very large or anatomically complex tori). Note signed vs verbal.
• Anesthesia — agent, concentration, vasoconstrictor, technique. Bilateral greater palatine blocks (at the greater palatine foramen, ~1 cm medial to the second/third molar gingival margin) plus nasopalatine block at the incisive foramen are the standard regional approach; supplemental local infiltration into the soft tissue overlying the torus completes anesthesia and improves hemostasis. Document the carpule count and any sedation codes (D9223 / D9230 / D9243 / D9248) used separately.
• Surgical code support — the "torus removal" line — explicit operative description of: incision design (Y-incision is the workhorse — single anteroposterior midline incision over the torus with bilateral anterior releasing limbs in the canine region; double-Y when posterior releases are needed; some surgeons use a midline incision alone for small dome-shaped tori); flap elevation (full-thickness mucoperiosteal flap reflected laterally bilaterally, periosteal elevator only — no sharp dissection over the torus apex where mucosa is thinnest); bone removal technique (bur sectioning into segments for lobulated or large tori, osteotome cleavage along the midline septum for flat or dome-shaped tori, mallet-and-osteotome only with adequate inferior support to avoid nasal floor fracture); recontouring (round bur, bone file, or rongeur to achieve a smooth ridge with no sharp edges); irrigation (copious sterile saline throughout to prevent thermal injury and clear bony debris); closure (primary closure of the Y-incision with interrupted sutures; periosteum apposed to underlying bone where possible to prevent dead space and hematoma); palatal stent or surgical pack (a pre-fabricated acrylic stent — often impressioned the visit before surgery — or a periodontal-pack-style dressing maintains pressure on the flap during the first 7-14 days, prevents hematoma, and protects the surgical site from food and tongue trauma).
• Surgical image support — intraoral photo of the elevated flap and exposed torus before reduction is increasingly expected on review by major commercial carriers and is the strongest piece of audit evidence on D7472 claims. A post-reduction photo confirming smooth contour and a post-op photo at suture-removal closes the loop. Photos labeled with patient identifier, date, and view (e.g., "midline torus palatinus, intraoperative pre-reduction, 2026-04-25").
• Specimen — bony fragments are typically discarded; submission to pathology is not routinely indicated for clinically obvious torus palatinus. Submit when the morphology is atypical, the clinical history is unusual (rapid growth, asymmetry, soft-tissue change), or the surgeon's index of suspicion for an osteoma, exostosis variant, or fibro-osseous lesion is non-zero. Document "specimen submitted to [lab] for histopathologic confirmation" or "specimen discarded — clinically diagnostic torus palatinus."
• Suture material and pattern — material (e.g., 4-0 chromic gut, 4-0 PGA, 3-0 silk), pattern (interrupted along the midline incision, releasing limbs sutured separately), count. Resorbable suture preferred for palatal sites — non-resorbable in a palatal stent under the tongue and bolus is a foreign-body irritant.
• Palatal stent / surgical pack — explicit documentation when used. Stent fabrication is typically a separate visit (impression at consult, lab fabrication, delivery on day of surgery). Stent removal at 7-14 days is the next-visit milestone.
• Hemostasis — achieved; method if notable (pressure with gauze, gelfoam in the residual bone bed, electrosurgery for soft-tissue bleeders, ligation of greater palatine artery if injured — rare but reportable). Document explicitly given the procedure's bleeding potential.
• Complications — explicit "None" or describe (mucosal perforation through the apex of the torus during flap reflection — repaired with primary suture; nasal floor exposure — managed with collagen plug and watertight closure; greater palatine artery injury — managed with pressure, hemostatic agent, ligation; intraoperative hypotension; failure to fully reduce the torus — staged approach planned).
• Patient tolerance / response — tolerated well, vitals stable, no adverse events, ambulatory dismissal with escort if sedated.
• Post-op instructions — soft diet 7-10 days (no chips, no crusty bread, no anything that can trap under a stent or traumatize the flap); pureed diet first 48 h if discomfort; no hot liquids 24 h; avoid strenuous activity 48-72 h; ice intermittent first 24 h then warm compresses to face for swelling; saltwater rinses starting 24 h post-op; do not remove the palatal stent except for cleaning if the practice has instructed home stent care; sleep with head elevated; return precautions (uncontrolled bleeding, severe disproportionate pain after 72 h, fever, foul taste or purulent discharge under the stent, stent dislodgement, exposed bone at stent removal). Verbal and written instructions documented.
• Prescriptions — analgesic regimen (ibuprofen 600 mg q6h prn ± acetaminophen 500 mg alternating per ADA / AAOMS NSAID-first guidance; D7472 post-op pain is often more severe than other pre-prosthetic procedures, and a short opioid course — e.g., hydrocodone-acetaminophen 5/325 q6h prn x 2-3 days — may be appropriate per practice protocol and state PMP rules); antibiotic per indication (no routine prophylaxis indicated for healthy patients per AAOMS clinical guidelines; consider amoxicillin 500 mg TID x 5-7 days for very large tori, prolonged operative time, immunocompromise, or active infection; clindamycin 300 mg QID for penicillin allergy noting C. diff risk); chlorhexidine 0.12% rinse BID starting 24 h post-op for plaque control around the stent; saline rinses for comfort. Document drug, dose, route, frequency, duration, and counseling on each.
• Next visit — post-op check at 7-10 days for stent removal and suture inspection (most chromic resorbs in this window); 3-week follow-up to assess complete mucosal coverage and palatal contour; prosthetic milestone linked to the indication (e.g., "denture impression appointment scheduled for 4 weeks post-op once palatal mucosa is fully healed and contour is stable" — typical prosthodontic practice waits 4-6 weeks before final impressions).
• Provider signature and any auxiliary operator initials.

Two phrases that defuse the most common audit questions on D7472: an explicit "interferes with planned maxillary prosthesis" statement linked to a same-arch removable prosthodontic code (D5110 / D5130 / D5213), and explicit dimension and morphology documentation supporting that the bony prominence is large enough to require excision rather than prosthesis modification. Both track the published carrier review criteria for pre-prosthetic surgery.

Common denial reasons

D7472 sits in the carrier "always-review" tier of pre-prosthetic surgical codes and carries meaningful audit exposure. The most frequent reasons it is denied, downgraded, or recouped:

• No documented prosthetic indication — the dominant denial. Chart cites "patient request" or "for cosmesis" with no removable prosthodontic plan, no documented mucosal ulceration, no functional impairment. Carrier denies as not medically necessary / cosmetic. Pair every D7472 claim with at least one covered indication (prosthetic interference, trauma from mastication, functional impairment, pathology-related interference).
• No same-arch removable prosthesis on file or planned — even with a covered indication on paper, carriers route D7472 to review when there is no D5110 / D5130 / D5213 on the recent claim history or treatment plan. Submit the prosthetic plan with the original claim or pre-determination.
• Missing torus dimensions — auditors treat absent measurement as a presumption that the bony prominence is small enough to manage with prosthesis relief rather than removal. "Lobulated torus" is not a measurement; "~22 mm A-P x 14 mm M-L x 6 mm vertical" is.
• No pre-op intraoral photo or imaging — the single most-requested piece of documentation when D7472 is reviewed. Carriers want to see the torus before the surgery.
• Site coded as D7472 but actually D7471 — a lateral palatal exostosis (off-midline, often associated with a buccal exostosis or alveolar shelf) coded as torus palatinus. Carrier re-codes to D7471 or denies; D7471 generally pays at a lower allowable than D7472.
• Bilateral palatal exostoses billed as two D7472 — D7472 is once per arch (one midline). Bilateral palatal lateral exostoses are two D7471 line items, not two D7472.
• No flap technique or operative detail — chart says "torus removed" without Y-incision design, flap elevation, sectioning technique, or recontouring. Carrier downgrades to "incidental bone removal" or denies for insufficient documentation.
• Default-template chart note — identical D7472 narrative across patients, no patient-specific dimensions or shape detail. Medicaid MCO recoupment programs flag template-fingerprint patterns.
• Cosmetic / "carcinophobia" framing — chart cites only patient anxiety about the prominence, with no clinical indication. Almost universally denied.
• No post-op stent or pack documented — auditors view absence of stent / surgical-pack documentation as evidence the procedure did not require pre-prosthetic-grade support, which weakens medical-necessity argument.
• Same-DOS billing of D7310 / D7311 same site — alveoloplasty of the area encompassing the torus is bundled into D7472. Bill alveoloplasty only when performed on a distinct quadrant or set of teeth/sites separate from the torus removal.
• Missing pathology disposition — chart silent on whether bony fragments were submitted or discarded. Most fragments are discarded as clinically obvious torus, but the chart should state the disposition.
• Operator signature / initials missing — auto-flagged by automated audit systems.

Related templates